Advertisement

Para- und autokrine Aspekte der Pathogenese des duktalen Pankreaskarzinoms: Einfluss von Zytokinen und Wachstumsfaktoren

  • Günter Schneider
  • Roland M. Schmid
Part of the Molekulare Medizin book series (MOLMED)

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

2.5.6 Literatur

  1. Aguirre AJ, Bardeesy N, Sinha M et al. (2003) Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17: 3112–3126PubMedGoogle Scholar
  2. Akhurst RJ, Derynck R (2001) TGF-β eta signaling in cancer — a double-edged sword Trends. Cell Biol 11: S44–S51Google Scholar
  3. Algul H, Adler G, Schmid RM (2002) NF-kappaB/Rel transcriptional pathway: Implications in pancreatic cancer. Int J Gastrointest Cancer 31: 71–78PubMedGoogle Scholar
  4. Apple SK, Hecht JR, Lewin DN, Jahromi SA, Grody WW, Nieberg RK (1999) Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: Evidence for multistep carcinogenesis. Hum Pathol 30: 123–129PubMedGoogle Scholar
  5. Arend WP (2002) The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 13: 323–340PubMedGoogle Scholar
  6. Arlt A, Vorndamm J, Muerkoster S et al. (2002) Autocrine production of interleukin 1beta confers constitutive nuclear factor kappaB activity and chemoresistance in pancreatic carcinoma cell lines. Cancer Res 62: 910–916PubMedGoogle Scholar
  7. Barton CM, Hall PA, Hughes CM, Gullick WJ, Lemoine NR (1991) Transforming growth factor alpha and epidermal growth factor in human pancreatic cancer. J Pathol 163: 111–116PubMedGoogle Scholar
  8. Blancher C, Moore JW, Robertson N, Harris AL (2001) Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3′-kinase/Akt signaling pathway. Cancer Res 61: 7349–7355PubMedGoogle Scholar
  9. Bono JS de, Rowinsky EK (2002) The ErbB receptor family: A therapeutic target for cancer. Trends Mol Med 8: S19–S26PubMedGoogle Scholar
  10. Bruick RK, McKnight SL (2001) A conserved family of pro-lyl-4-hydroxylases that modify HIF. Science 294: 1337–1340PubMedGoogle Scholar
  11. Bruns CJ, Solorzano CC, Harbison MT et al. (2000) Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res 60: 2926–2935PubMedGoogle Scholar
  12. Buchler P, Reber HA, Buchler MC et al. (2001) Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (herceptin). J Gastrointest Surg 5: 139–146PubMedGoogle Scholar
  13. Burgess AW, Cho HS, Eigenbrot C et al. (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12: 541–552PubMedGoogle Scholar
  14. Calonge MJ, Massague J (1999) Smad4/DPC4 silencing and hyperactive Ras jointly disrupt transforming growth factor-beta antiproliferative responses in colon cancer cells. J Biol Chem 274: 33637–33643PubMedGoogle Scholar
  15. Chiao PJ, Hunt KK, Grau AM et al. (1999) Tumor suppressor gene Smad4/DPC4, its downstream target genes, and regulation of cell cycle. Ann NY Acad Sci 880: 31–37PubMedGoogle Scholar
  16. Chinkers M, Cohen S (1981) Purified EGF receptor-kinase interacts specifically with antibodies to Rous sarcoma virus transforming protein. Nature 290: 516–519PubMedGoogle Scholar
  17. Cockman ME, Masson N, Mole DR et al. (2000) Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275: 25733–25741PubMedGoogle Scholar
  18. Cohen S, Ushiro H, Stoscheck C, Chinkers M (1982) A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J Biol Chem 257: 1523–1531PubMedGoogle Scholar
  19. Colotta F, Dower SK, Sims JE, Mantovani A (1994) The type II ‘decoy’ receptor: A novel regulatory pathway for interleukin 1. Immunol Today 15: 562–526PubMedGoogle Scholar
  20. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L (2003) VEGF-receptor signal transduction. Trends Biochem Sci 28: 488–494PubMedGoogle Scholar
  21. Dankort DL, Muller WJ (2000) Signal transduction in mammary tumorigenesis: A transgenic perspective. Oncogene 19: 1038–1044PubMedGoogle Scholar
  22. Day JD, Digiuseppe JA, Yeo C et al. (1996) Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms. Hum Pathol 27: 119–124PubMedGoogle Scholar
  23. Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-β eta family signalling. Nature 425: 577–584PubMedGoogle Scholar
  24. Dickson RB, Lippman ME (1995) Growth factors in breast cancer. Endocr Rev 16: 559–589PubMedGoogle Scholar
  25. Dijke P ten, Hill CS (2004) New insights into TGF-beta-Smad signalling. Trends Biochem Sci 29: 265–273PubMedGoogle Scholar
  26. Dinarello CA (1997) Interleukin-1. Cytokine Growth Factor Rev 8: 253–265PubMedGoogle Scholar
  27. Downward J, Yarden Y, Mayes E et al. (1984) Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. Nature 307: 521–527PubMedGoogle Scholar
  28. Ebert M, Yokoyama M, Kobrin MS et al. (1994) Induction and expression of amphiregulin in human pancreatic cancer. Cancer Res 54: 3959–3962PubMedGoogle Scholar
  29. Ellenrieder V, Hendler SF, Boeck W et al. (2001a) Transforming growth factor beta1 treatment leads to an epithelial-mesenchymal transdifferentiation of pancreatic cancer cells requiring extracellular signal-regulated kinase 2 activation. Cancer Res 61: 4222–4228PubMedGoogle Scholar
  30. Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G, Gress TM (2001b) TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloprotei-nase-2 and the urokinase plasminogen activator system. Int J Cancer 93: 204–211PubMedGoogle Scholar
  31. Epstein AC, Gleadle JM, McNeill LA et al. (2001) C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43–54PubMedGoogle Scholar
  32. Estrov Z, Kurzrock R, Wetzler M et al. (1991) Suppression of chronic myelogenous leukemia colony growth by inter-leukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: A novel application for inhibitors of IL-1 activity Blood 78: 1476–1484PubMedGoogle Scholar
  33. Farrow B, Evers BM (2002) Inflammation and the development of pancreatic cancer. Surg Oncol 10: 153–169PubMedGoogle Scholar
  34. Forsythe JA, Jiang BH, Iyer NV et al. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604–4613PubMedGoogle Scholar
  35. Friess H, Yamanaka Y, Buchler M et al. (1993) Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105: 1846–1856PubMedGoogle Scholar
  36. Furuya N, Kawa S, Akamatsu T, Furihata K (1997) Long-term follow-up of patients with chronic pancreatitis and K-ras gene mutation detected in pancreatic juice. Gastroenterology 113: 593–598PubMedGoogle Scholar
  37. Gansauge S, Gansauge F, Ramadani M et al. (1997) Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res 57: 1634–1637PubMedGoogle Scholar
  38. Ghosh S, May MJ, Kopp EB (1998) NF-kappa B and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16: 225–260PubMedGoogle Scholar
  39. Goggins M, Shekher M, Turnacioglu K, Yeo Cj, Hruban RH, Kern SE (1998) Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 58: 5329–5332PubMedGoogle Scholar
  40. Grau AM, Zhang L, Wang W et al. (1997) Induction of p21wafl expression and growth inhibition by transforming growth factor beta involve the tumor suppressor gene DPC4 in human pancreatic adenocarcinoma cells. Cancer Res 57: 3929–3934PubMedGoogle Scholar
  41. Graus-Porta D, Beerli RR, Daly JM, Hynes NE (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. Embo J 16: 1647–1655PubMedGoogle Scholar
  42. Greenfeder SA, Nunes P, Kwee L, Labow M, Chizzonite RA, Ju G (1995) Molecular cloning and characterization of a second subunit of the interleukin 1 receptor complex. J Biol Chem 270: 13757–13765PubMedGoogle Scholar
  43. Greten FR, Wagner M, Weber CK, Zechner U, Adler G, Schmid RM (2001) TGF alpha transgenic mice. A model of pancreatic cancer development Pancreatology 1: 363–368Google Scholar
  44. Gullick WJ, Love SB, Wright C et al. (1991) c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63: 434–438PubMedGoogle Scholar
  45. Hahn SA, Bartsch D, Schroers A et al. (1998) Mutations of the DPC4/Smad4 gene in biliary tract carcinoma. Cancer Res 58: 1124–1126PubMedGoogle Scholar
  46. Hahn SA, Schutte M, Hoque AT et al. (1996) DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350–353PubMedGoogle Scholar
  47. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100: 57–70PubMedGoogle Scholar
  48. Hingorani SR, Petricoin EF, Maitra A et al. (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4: 437–450PubMedGoogle Scholar
  49. Holbro T, Hynes NE (2004) ErbB receptors: Directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol 44: 195–217PubMedGoogle Scholar
  50. Holbro T, Civenni G, Hynes NE (2003) The ErbB receptors and their role in cancer progression. Exp Cell Res 284: 99–110PubMedGoogle Scholar
  51. Hotz HG, Reber HA, Hotz B et al. (2001) Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth. J Gastrointest Surg 5: 131–138PubMedGoogle Scholar
  52. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW (1991) The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5: 1806–1814PubMedGoogle Scholar
  53. Hruban RH, Wilentz RE, Kern SE (2000) Genetic progression in the pancreatic ducts. Am J Pathol 156: 1821–1825PubMedGoogle Scholar
  54. Hsieh TC, Chiao JW (1995) Growth modulation of human prostatic cancer cells by interleukin-1 and interleukin-1 receptor antagonist. Cancer Lett 95: 119–123PubMedGoogle Scholar
  55. Ijichi H, Otsuka M, Tateishi K et al. (2004) Smad4-independent regulation of p21/WAFl by transforming growth factor-beta. Oncogene 23: 1043–1051PubMedGoogle Scholar
  56. Ikeda N, Adachi M, Taki T et al. (1999) Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer 79: 1553–1563PubMedGoogle Scholar
  57. Itakura J, Ishiwata T, Friess H et al. (1997) Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res 3: 1309–1316PubMedGoogle Scholar
  58. Itakura J, Ishiwata T, Shen B, Kornmann M, Korc M (2000) Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cance. Int J Cancer 85: 27–34PubMedGoogle Scholar
  59. Jemal A, Thomas A, Murray T, Thun M (2002) Cancer statistics, 2002. CA Cancer J Clin 52: 23–47PubMedGoogle Scholar
  60. Jonson T, Gorunova L, Dawiskiba S et al. (1999) Molecular analyses of the 15q and 18q SMAD genes in pancreatic cancer. Genes Chromosomes Cancer 24: 62–71PubMedGoogle Scholar
  61. Jussila L, Alitalo K (2002) Vascular growth factors and lymphangiogenesis. Physiol Rev 82: 673–700PubMedGoogle Scholar
  62. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW (2000) Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 97: 10430–10435PubMedGoogle Scholar
  63. Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2: 301–310PubMedGoogle Scholar
  64. King CR, Kraus MH, Aaronson SA (1985) Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 229: 974–976PubMedGoogle Scholar
  65. Kleeff J, Ishiwata T, Maruyama H et al. (1999 a) The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 18: 5363–5372PubMedGoogle Scholar
  66. Kleeff J, Kusama T, Rossi DL et al. (1999 b) Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int J Cancer 81: 650–657PubMedGoogle Scholar
  67. Kleeff J, Maruyama H, Friess H, Buchler MW, Falb D, Korc M (1999 c) Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Biochem Biophys Res Commun 255: 268–273PubMedGoogle Scholar
  68. Kobrin MS, Funatomi H, Friess H, Buchler MW, Stathis P, Korc M (1994) Induction and expression of heparin-binding EGF-like growth factor in human pancreatic cancer. Biochem Biophys Res Commun 202: 1705–1709PubMedGoogle Scholar
  69. Koka V, Potti A, Koch M, Fraiman G, Mehdi S, Levitt R (2002) Role of immunohistochemical identification of Her-2/neu and detection of variability in overexpression in pancreatic carcinoma. Anticancer Res 22: 1593–1597PubMedGoogle Scholar
  70. Korc M (2003) Pathways for aberrant angiogenesis in pancreatic cancer. Mol Cancer 2: 8PubMedGoogle Scholar
  71. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG (1992) Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest 90: 1352–1360PubMedGoogle Scholar
  72. Kretzschmar M, Doody J, Timokhina I, Massague J (1999) A mechanism of repression of TGFbeta/ Smad signaling by oncogenic Ras. Genes Dev 13: 804–816PubMedGoogle Scholar
  73. Kukk E, Lymboussaki A, Taira S et al. (1996) VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122: 3829–3837PubMedGoogle Scholar
  74. Le X, Shi Q, Wang B et al. (2000) Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res 20: 935–946PubMedGoogle Scholar
  75. Lei S, Appert HE, Nakata B, Domenico DR, Kim K, Howard JM (1995) Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival. Int J Pancreatol 17: 15–21PubMedGoogle Scholar
  76. Lemoine NR, Hughes CM, Barton CM et al. (1992) The epidermal growth factor receptor in human pancreatic cancer. J Pathol 166: 7–12PubMedGoogle Scholar
  77. Liptay S, Weber Ck, Ludwig L, Wagner M, Adler G, Schmid RM (2003) Mitogenic and antiapoptotic role of constitutive NF-kappaB/Rel activity in pancreatic cancer. Int J Cancer 105: 735–746PubMedGoogle Scholar
  78. Luo J, Guo P, Matsuda K et al. (2001) Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer 92: 361–369PubMedGoogle Scholar
  79. Marschall Z von, Cramer T, Hocker M et al. (2000) De novo expression of vascular endothelial growth factor in human pancreatic cancer: Evidence for an autocrine mitogenic loop. Gastroenterology 119: 1358–1372Google Scholar
  80. Massague J (1998) TGF-beta signal transduction. Annu Rev Biochem 67: 753–791PubMedGoogle Scholar
  81. Massague J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103: 295–309PubMedGoogle Scholar
  82. Massague J, Pandiella A (1993) Membrane-anchored growth factors. Annu Rev Biochem 62: 515–541PubMedGoogle Scholar
  83. Matsuura I, Denissova NG, Wang G, He D, Long J, Liu F (2004) Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 430: 226–231PubMedGoogle Scholar
  84. Maxwell PH, Wiesener MS, Chang GW et al. (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271–275PubMedGoogle Scholar
  85. Meadows KN, Bryant P, Pumiglia K (2001) Vascular endothelial growth factor induction of the angiogenic phenotype requires Ras activation. J Biol Chem 276: 49289–49298PubMedGoogle Scholar
  86. Metzen E, Berchner-Pfannschmidt U, Stengel P et al. (2003) Intracellular localisation of human HIF-1 alpha hydroxylases: Implications for oxygen sensing. J Cell Sci 116: 1319–1326PubMedGoogle Scholar
  87. Miyamoto Y, Maitra A, Ghosh B et al. (2003) Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3: 565–576PubMedGoogle Scholar
  88. Muerkoster S, Arlt A, Gehrz A et al. (2004 a) Autocrine IL-1beta secretion leads to NF-kappabeta-mediated chemoresistance in pancreatic carcinoma cells in vivo. Med Klin (Munich) 99: 185–190Google Scholar
  89. Muerkoster S, Wegehenkel K, Arlt A et al. (2004b) Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. Cancer Res 64: 1331–1337PubMedGoogle Scholar
  90. Niu J, Li Z, Peng B, Chiao PJ (2004) Identification of an autoregulatory feedback pathway involving interleukin-1alpha in induction of constitutive NF-kappaB activation in pancreatic cancer cells. J Biol Chem 279: 16452–16462PubMedGoogle Scholar
  91. Oelmann E, Kraemer A, Serve H et al. (1997) Autocrine interleukin-1 receptor antagonist can support malignant growth of glioblastoma by blocking growth-inhibiting autocrine loop of interleukin-1. Int J Cancer 71: 1066–1076PubMedGoogle Scholar
  92. Ohh M, Park CW, Ivan M et al. (2000) Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2: 423–427PubMedGoogle Scholar
  93. Okada F, Rak JW, Croix BS et al. (1998) Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc Natl Acad Sci USA 95: 3609–3614PubMedGoogle Scholar
  94. Ozawa F, Friess H, Tempia-Caliera A, Kleeff J, Buchler MW (2001) Growth factors and their receptors in pancreatic cancer. Teratog Carcinog Mutagen 21: 27–44PubMedGoogle Scholar
  95. Park JE, Keller GA, Ferrara N (1993) The vascular endothelial growth factor (VEGF) isoforms: Differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 4: 1317–1326PubMedGoogle Scholar
  96. Paterson MC, Dietrich KD, Danyluk J et al. (1991) Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 51: 556–567PubMedGoogle Scholar
  97. Paul SA, Simons JW, Mabjeesh NJ (2004) HIF at the crossroads between ischemia and carcinogenesis. J Cell Physiol 200: 20–30PubMedGoogle Scholar
  98. Pino SM, Xiong HQ, McConkey D, Abbruzzese JL (2004) Novel therapies for pancreatic adenocarcinoma. Curr Gastroenterol Rep 6: 119–125PubMedGoogle Scholar
  99. Poch B, Gansauge F, Schwarz A et al. (2001) Epidermal growth factor induces cyclin Dl in human pancreatic carcinoma: Evidence for a cyclin D1-dependent cell cycle progression. Pancreas 23: 280–287PubMedGoogle Scholar
  100. Rangarajan A, Weinberg RA (2003) Opinion: Comparative biology of mouse versus human cells: Modelling human cancer in mice. Nat Rev Cancer 3: 952–959PubMedGoogle Scholar
  101. Roskoski R Jr. (2004) The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 319: 1–11PubMedGoogle Scholar
  102. Rowland-Goldsmith MA, Maruyama H, Kusama T, Ralli S, Korc M (2001) Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. Clin Cancer Res 7: 2931–2940PubMedGoogle Scholar
  103. Rowland-Goldsmith MA, Maruyama H, Matsuda K et al. (2002) Soluble type II transforming growth factor-beta receptor attenuates expression of metastasis-associated genes and suppresses pancreatic cancer cell metastasis. Mol Cancer Ther 1: 161–167PubMedGoogle Scholar
  104. Rozenblum E, Schutte M, Goggins M et al. (1997) Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 57: 1731–1734PubMedGoogle Scholar
  105. Sandgren EP, Luetteke NC, Palmiter RD, Brinster RL, Lee DC (1990) Overexpression of TGF alpha in transgenic mice: Induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61: 1121–1135PubMedGoogle Scholar
  106. Sawai H, Takeyama H, Yamamoto M et al. (2003) Enhancement of integrins by interleukin-1alpha, and their relationship with metastatic and invasive behavior of human pancreatic ductal adenocarcinoma cells. J Surg Oncol 82: 51–56PubMedGoogle Scholar
  107. Schlieman MG, Fahy BN, Ramsamooj R, Beckett L, Bold RJ (2003) Incidence, mechanism and prognostic value of activated AKT in pancreas cancer. Br J Cancer 89: 2110–2115PubMedGoogle Scholar
  108. Schneider G, Schmid RM (2003) Genetic alterations in pancreatic carcinoma. Mol Cancer 2: 15PubMedGoogle Scholar
  109. Schutte M, Hruban RH, Hedrick L et al. (1996) DPC4 gene in various tumor types. Cancer Res 56: 2527–2530PubMedGoogle Scholar
  110. Semenza GL (2001) HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol 13: 167–171PubMedGoogle Scholar
  111. Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K (2000) High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88: 2239–2245PubMedGoogle Scholar
  112. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593–602PubMedGoogle Scholar
  113. Seufferlein T, Van Lint J, Liptay S, Adler G, Schmid RM (1999) Transforming growth factor alpha activates Ha-Ras in human pancreatic cancer cells with Ki-ras mutations. Gastroenterology 116: 1441–1452PubMedGoogle Scholar
  114. Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, Xie K (1999) Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 5: 3711–3721PubMedGoogle Scholar
  115. Shi Q, Le X, Abbruzzese JL et al. (2001) Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res 61: 4143–4154PubMedGoogle Scholar
  116. Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685–700PubMedGoogle Scholar
  117. Shibuya M (2001) Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 26: 25–35PubMedGoogle Scholar
  118. Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2N. Engl J Med 344: 783–792Google Scholar
  119. Stebbins CE, Kaelin WG Jr, Pavletich NP (1999) Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284: 455–461PubMedGoogle Scholar
  120. Subramanian G, Schwarz RE, Higgins L et al. (2004) Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. Cancer Res 64: 5200–5211PubMedGoogle Scholar
  121. Sutherland RL, Musgrove EA (2002) Cyclin Dl and mammary carcinoma: New insights from transgenic mouse models. Breast Cancer Res 4: 14–17PubMedGoogle Scholar
  122. Talks KL, Turley H, Gatter KC et al. (2000) The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol 157: 411–421PubMedGoogle Scholar
  123. Tanimoto K, Makino Y, Pereira T, Poellinger L (2000) Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. Embo J 19: 4298–4309PubMedGoogle Scholar
  124. Tao M, Li B, Nayini J et al. (2000) SCF, IL-1beta, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patients. Cytokine 12: 699–707PubMedGoogle Scholar
  125. Tascilar M, Skinner HG, Rosty C et al. (2001) The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res 7: 4115–4121PubMedGoogle Scholar
  126. Villanueva A, Garcia C, Paules AB et al. (1998) Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells Oncogene 17: 1969–1978PubMedGoogle Scholar
  127. Wagner M, Greten FR, Weber CK et al. (2001) A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Genes Dev 15: 286–293PubMedGoogle Scholar
  128. Wagner M, Luhrs H, Kloppel G, Adler G, Schmid RM (1998) Malignant transformation of duct-like cells originating from acini in transforming growth factor transgenic mice. Gastroenterology 115: 1254–1262PubMedGoogle Scholar
  129. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ (1999) The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5: 119–127PubMedGoogle Scholar
  130. Wei D, Le X, Zheng L et al. (2003) Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22: 319–329PubMedGoogle Scholar
  131. Wetzler M, Kurzrock R, Estrov Z et al. (1994) Altered levels of interleukin-1 beta and interleukin-1 receptor antagonist in chronic myelogenous leukemia: clinical and prognostic correlates. Blood 84: 3142–3147PubMedGoogle Scholar
  132. Whitcomb DC, Pogue-Geile K (2002) Pancreatitis as a risk for pancreatic cancer. Gastroenterol Clin North Am 31: 663–678PubMedGoogle Scholar
  133. Wilentz RE, Iacobuzio-Donahue CA, Argani P et al. (2000) Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: Evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 60: 2002–2006PubMedGoogle Scholar
  134. Xiong HQ, Abbruzzese JL (2002) Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 29: 31–37PubMedGoogle Scholar
  135. Yamada Y, Karasaki H, Matsushima K, Lee GH, Ogawa K (1999) Expression of an IL-1 receptor antagonist during mouse hepatocarcinogenesis demonstrated by differential display analysis. Lab Invest 79: 1059–1067PubMedGoogle Scholar
  136. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M (1993) Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 13: 565–569PubMedGoogle Scholar
  137. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127–137PubMedGoogle Scholar
  138. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS (2002) Effect of p53 status on tumor response to antiangiogenic therapy. Science 295: 1526–1528PubMedGoogle Scholar
  139. Zhao J, Buick RN (1995) Regulation of transforming growth factor beta receptors in H-ras oncogene-transformed rat intestinal epithelial cells. Cancer Res 55: 6181–6188PubMedGoogle Scholar
  140. Zhong H, De Marzo AM, Laughner E et al. (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases Cancer Res 59: 5830–5833PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • Günter Schneider
    • 1
  • Roland M. Schmid
    • 1
  1. 1.Klinikum rechts der Isar, II. Medizinische Klinik und PoliklinikTechnische Universität MünchenMünchen

Personalised recommendations